BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China

被引:16
|
作者
Zheng, Xiangqian [1 ]
Xia, Tingting [1 ]
Lin, Lin [1 ]
Gao, Songyuan [3 ]
Lee, Yigong [1 ]
Yu, Yang [1 ]
Wei, Songfeng [1 ]
Gao, Ming [1 ,2 ]
机构
[1] Tianjin Med Univ, Canc Inst & Hosp, Oncol Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
[2] Tianjin Med Univ, Canc Hosp & Inst, Dept Thyroid & Neck Tumor, Tianjin 300060, Peoples R China
[3] Tsinghua Univ, Dept Pathol, Tsinghua Univ Med Coll, Beijing 100084, Peoples R China
来源
WORLD JOURNAL OF SURGICAL ONCOLOGY | 2012年 / 10卷
关键词
Papillary thyroid carcinoma; Multiple PTC; Solitary PTC; BRAF(V600E) mutation; BRAF MUTATIONS; INTRAGLANDULAR DISSEMINATION; CANCER; MICROCARCINOMA; PREVALENCE; GENE; METAANALYSIS; INVOLVEMENT; METASTASIS; FEATURES;
D O I
10.1186/1477-7819-10-104
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Papillary thyroid carcinoma (PTC) is one of the most frequent endocrine malignancies. In most cases, it often presents as multifocal tumor. It has been reported that multifocal tumors are associated with elevated risk of lymph node and distant metastases. Multifocality is also one of the factors predicting prognosis. Recent studies show that BRAF(V600E) mutation occurs more frequently in aggressive PTC. The purpose of this study was to evaluate BRAF(V600E) status and clinicopathological features in multiple and solitary PTC. Methods: We performed a retrospective study to analyze 512 PTC cases who received surgery, including 376 solitary PTCs and 136 multiple PTCs. Results: Multiple PTC is more related to lymph node metastasis and vascular invasion than solitary PTC. However, the distant metastasis rate and 10-year survival rate showed no difference between these two groups. BRAF(V600E) mutation status was more frequent in multiple PTC patients with lymph node metastasis and late stage at diagnosis. Conclusion: BRAF(V600E) mutation is most commonly associated with extra-thyroidal extension and lymph node metastasis in PTC. Multiple PTC patients with young age, large tumors and BRAF(V600E) mutation should be followed carefully. Our study provides useful information for PTC patients' followup and treatment.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] The relevance of the BRAFV600E mutation in the treatment of the Papillary Thyroid Carcinoma
    Ajuria, O.
    Navarro Martinez, T.
    Lorente Castro, B.
    Castro Beiras, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S652 - S652
  • [22] Utilization of a MAB for BRAFV600E detection in papillary thyroid carcinoma
    Bullock, M.
    O'Neill, C.
    Chou, A.
    Clarkson, A.
    Dodds, T.
    Toon, C.
    Sywak, M.
    Sidhu, S. B.
    Delbridge, L. W.
    Robinson, B. G.
    Learoyd, D. L.
    Capper, D.
    von Deimling, A.
    Clifton-Bligh, R. J.
    Gill, A. J.
    ENDOCRINE-RELATED CANCER, 2012, 19 (06) : 779 - 784
  • [23] BRAFV600E mutational status in thyroid carcinoma patients - single center study
    Makazlieva, T.
    Manevska, N.
    Stojanoski, S.
    Jankulovska, A.
    Stoilovska, B.
    Eftimov, A.
    Jovanovic, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S436 - S436
  • [24] Clinical significance of BRAFV600E and TERT promoter mutation in papillary thyroid microcarcinoma
    Jincai Xue
    Qinjiang Liu
    Youxin Tian
    Xiaofeng Hou
    OncologyandTranslationalMedicine, 2019, 5 (02) : 75 - 79
  • [25] Clinical and Sonographic Differences Between RET Fusion-positive and BRAFV600E in Papillary Thyroid Carcinoma
    Chen, Zixian
    Sun, Wenyu
    Fei, Mengjia
    Qian, Kai
    Shi, Yuan
    Guo, Kai
    Wang, Zhuoying
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,
  • [26] Analysis of BRAFV600E Mutational Status and the Biology of Papillary Thyroid Microcarcinoma
    Han, Y.
    Sacks, W.
    Treml, A.
    Fan, X.
    Bose, S.
    Lopategui, J.
    Braunstein, G.
    Frishberg, D.
    LABORATORY INVESTIGATION, 2011, 91 : 137A - 137A
  • [27] Analysis of BRAFV600E Mutational Status and the Biology of Papillary Thyroid Microcarcinoma
    Han, Y.
    Sacks, W.
    Treml, A.
    Fan, X.
    Bose, S.
    Lopategui, J.
    Braunstein, G.
    Frishberg, D.
    MODERN PATHOLOGY, 2011, 24 : 137A - 137A
  • [28] Animal Model of the Papillary Thyroid Carcinoma Induced by BRAFV600E Mutation
    Rusinek, D.
    Chmielik, E.
    Kowal, M.
    Swierniak, M.
    Kowalska, M.
    Oczko-Wojciechowska, M.
    Przeorek, C.
    Widlak, W.
    Jarzab, B.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S166 - S167
  • [29] Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation
    Huang, Yongbo
    Liao, Denghui
    Pan, Lingxiao
    Ye, Runyi
    Li, Xiaoxi
    Wang, Shenming
    Ye, Caisheng
    Chen, Liuhua
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (05) : 675 - 681
  • [30] BRAFV600E Detection for Papillary Thyroid Carcinoma by LUNA ARMS PCR
    Smith, G. D.
    Zhou, L.
    Rowe, L. R.
    Chadwick, B. E.
    Jarboe, E. A.
    Wittwer, C. T.
    Collins, B. T.
    MODERN PATHOLOGY, 2011, 24 : 106A - 106A